At the time of writing, Cardiff Oncology Inc [CRDF] stock is trading at $3.08, down -2.84%. An important factor to consider is whether the stock is rising or falling in short-term value. The CRDF shares have gain 15.79% over the last week, with a monthly amount glided 27.80%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cardiff Oncology Inc [NASDAQ: CRDF] stock has seen the most recent analyst activity on January 05, 2026, when Noble Capital Markets initiated its Outperform rating and assigned the stock a price target of $12. Previously, Ladenburg Thalmann started tracking the stock with Buy rating on July 08, 2025, and set its price target to $19. On June 24, 2025, Jefferies initiated with a Hold rating and assigned a price target of $3.50 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $8 on September 06, 2024. William Blair initiated its recommendation with a Outperform. Robert W. Baird started tracking with a Outperform rating for this stock on December 08, 2021, and assigned it a price target of $19.
For the past year, the stock price of Cardiff Oncology Inc fluctuated between $1.90 and $4.99. Cardiff Oncology Inc [NASDAQ: CRDF] shares were valued at $3.08 at the most recent close of the market.
Analyzing the CRDF fundamentals
According to Cardiff Oncology Inc [NASDAQ:CRDF], the company’s sales were 0.50M for trailing twelve months, which represents an -27.27% plunge. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -140.96%, Pretax Profit Margin comes in at -132.37%, and Net Profit Margin reading is -132.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.79, Equity is -0.77 and Total Capital is -1.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Cardiff Oncology Inc [NASDAQ:CRDF] has a current ratio of 4.20. On the other hand, the Quick Ratio is 4.20, and the Cash Ratio is 0.69. Considering the valuation of this stock, the price to sales ratio is 427.06, the price to book ratio is 4.24.
Transactions by insiders
Recent insider trading involved PACE GARY W, Director, that happened on Jul 30 ’25 when 0.28 million shares were purchased. Director, PACE GARY W completed a deal on Jul 30 ’25 to buy 15000.0 shares.
